Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1 
Materials and methods
This study included 90 patients, who were positive for HCV infection by reverse transcription PCR, divided into three groups: group I (Gr I) included 30 patients with chronic hepatitis C, group II (Gr II) included 30 patients with liver cirrhosis in addition to group III (Gr III) of 30 patients with HCC. Reverse transcription PCR analysis was performed to determine the expression profile of IRF-1, IRF-3, and IRF-7 genes extracted from the peripheral blood mononuclear cells of those patients.
Results IRF-1expression was significantly higher (P < 0.001) in patients of Gr I (86.6%) compared with those in Gr II (46.7%) and Gr III (36.7%), whereas IRF-3 expression was significantly higher (P < 0.005) among patients of Gr II (73.3%) in comparison with that in Gr I (50%) and Gr III (36.7%). In contrast, although expression of IRF-7 was higher in Gr II than in the other groups, there was no statistically significant difference (P > 0.05).
Conclusion Alterations in IRFs expression might be considered as markers associated with a higher risk of cirrhosis in patients with chronic HCV infection. Expression of IRF-1 and IRF-3 were more prevalent in patients with chronic HCV and cirrhosis, respectively, in comparison with HCC patients. Thus, IRF-1 could be nominated as one of the tumor suppressor factors and could aid in the early detection of HCC. Eur J Gastroenterol 
Introduction
Hepatitis C virus (HCV) is one of the most important pathogens causing liver-related morbidity and mortality [1, 2] . After a subclinical phase, patient progress to persistent HCV infection, which is the leading cause of chronic liver disease (CLD) associated with cirrhosis and hepatocellular carcinoma (HCC) [3] . Viral persistence is linked to the ability of HCV to evade and/or antagonize the host immune response at both the local and systemic levels.
Interferon (IFN) plays a central role in eliminating HCV, not only following clinical therapeutic application but also as a cellular immune response [4, 5] . Cellular innate responses are mediated by the IFN-stimulated genes (ISGs) [6] . Thus, the role of IFN in HCV infection is crucial and clarification of the mechanisms involved in impaired anti-HCV actions by IFN-a is an important goal for the definition of effective therapies [7] . The antiviral mechanism of IFN is accomplished through human IFN receptors. They are divided into type I IFN-R which can combine with IFN-a/b, and type II IFN-R which is sensitive to IFN-g in addition to IFN-a/b to some extent [8] . Genes containing an IFN-stimulated response element (ISRE) can be divided into two groups according to the induction by IFN and virus infection: one induced only by IFN and the other induced by both IFN and virus infection [9] .
IFN results in activation or direct induction of a set of transcription factors, interferon regulatory factors (IRFs), which are a family involved in the regulation of IFNs and IFN inducible genes [10, 11] . IRF-1, IRF-2, and IRF-9 are critical for proper IFN-dependent gene expression, whereas IRF-3 and IRF-7 have been shown to play an essential role in virus-dependent signaling [12, 13] . IRF-1 is one of the key cellular factors that modulate levels of ISRE-regulated ISG expression and predominantly affect the intracellular replication of HCV genomic RNA [14] . IRF-3 negatively regulates intracellular HCV replication, and was partially activated in cells that expressed the HCV replicon. Thus, IRF-3 is a key molecule that can control HCV replication through modulation of host IFN gene responses [15] . IRF-7, as one of the ISGs synthesized, regulates the transcription of IFN-a genes [16] and is essential for the induction of type I IFN through a virus-mediated manner [17] .
The relationship between IRF-1, IRF-3, and IRF-7 expression and their role as markers of host factors associated with a higher risk of disease progression in patients with chronic HCV infection have not been well studied. Therefore, this study has been carried out to examine the alteration in the expression of IRFs (IRF-1, IRF-3, and IRF-7) and their relation to the laboratory findings in Egyptian patients with HCV-related CLD and HCC; also the possible use of IRF-1 as an early predictor of cirrhosis and HCC will be addressed.
Materials and methods

Patients
This study included 90 patients with postHCV infection CLDs, who were positive for HCV infection by reverse transcription PCR. 
RNA extraction
Blood samples were collected from all patients for the peripheral blood mononuclear cells (PBMC) separation using the Ficoll-Hypaque (Amersham/Pharmacia, Piscataway, New Jersey, USA). The PBMC were lysed in 1 ml of TRI reagent (Molecular Research Center Inc., Cincinnati, Ohio, USA). The PBMC lysate was mixed with 1-bromo-3-chloropropane phase separation agent for 1 min and incubated at room temperature for 15 min. After centrifugation for 15 min with a speed of 12 000 rpm at 41C, RNA was precipitated from the supernatant overnight at -201C with an equal volume of isopropanol and 1/10 volume of 7.5 mol/l ammonium acetate. The precipitate was washed twice with 75% ethanol and then once with 95% ethanol. RNA was briefly air dried and then was further purified using RNeasy columns (QIAGEN, Valencia, California, USA). The amount and quality of RNA were determined by spectrophotometry and by electrophoresis through 1% agarose with ethidium bromide.
Reverse transcription PCR technique
One microgram of total RNA was reverse transcribed to c-DNA with oligo (dt) primers in a 25-ml reaction mix as described earlier. From this mixture of c-DNA, IRF-1, IRF-3, IRF-7, and b-actin genes were amplified by PCR as described earlier [18, 19] . Primers used for IRF-1: 5 0 -CAG AGGAAAGAGAGAAAGTCC-3 0 was used for IRF-1 sense, and 5 0 -CACACGGTGACAGTGCTGG-3 0 was used for IRF-1 antisense. Primers used for IRF-3: 5 0 -ACCAGCC GTGGACCAAGAG-3 0 was used for IRF-3 sense, and 5 0 -T ACCAAGGCCCTGAGGCAC-3 0 was used for IRF-3 antisense. Primers used for IRF-7: 5 0 -TGGTCCTGGTGAAG CTGGAA-3 0 was used for IRF-7 sense, and 5 0 -GATGTCG TCATAGAGGCTGTTGG-3 0 was used for IRF-7 antisense. In case of b-actin as amplification control, we used primers for b-actin sense 5 0 -ATTGCCGACA GGATGCA GAA-3 0 , and primers for b-actin antisense 5 0 -CAAGAT CATT GCTCCTCCTG AGCGCA-3 0 .
Hepatitis C virus detection by reverse transcription PCR
Nucleic acid extraction was carried out by the QIAGEN viral RNA Mini-extraction kit (QIAGEN) using 140 ml of patient serum according to the manufacturer's procedure. Reverse transcription-PCR was performed as described earlier [20] . After completion of the amplification reaction, 10 ml of each PCR reaction product was analyzed by electrophoresis through an agarose 1.2% gel stained by ethidium bromide in Tris-acetate-EDTA buffer (pH 8.0) and DNA was transferred from the gel onto a nitrocellulose filter with alkaline buffer (4 N NaOH).
The transferred DNA was cross-linked by incubation for 2-3 h at 801C and the blot was then hybridized with an internal probe [20] . 
Results
Clinical findings
The clinical and laboratory data of the different studied groups are shown in Table 1 . There was a statistically significant difference among the studied groups regarding hemoglobin percentage, platelet count, ALT, prothrombin concentration, and serum albumin concentration, with the lowest values towards Gr III and serum a-fetoprotein (AFP) of the highest values towards Gr III.
Expression of interferon regulatory factors (IRF-1, IRF-3, and IRF-7) Table 2 shows that IRF-1 expression was detected in 26 of 30 (86.6%) chronic HCV patients, whereas IRF-1 expression was detected in 14 of 30 (36.7%) HCC cases (P < 0.001).
In addition, a statistically significant difference among the studied groups was found with the prevalence of IRF-3, most frequently towards Gr II with liver cirrhosis on top of HCV infection (73.3%) (P < 0.05), whereas there was no statistically significant difference among the studied groups regarding the prevalence of IRF-7 (P > 0.05).
IRF-1 expression in relation to laboratory data
There was a statistically significant difference between patients with positive and negative IRF-1 regarding serum AFP of Gr I, aspirate transaminase (AST) and ALT of Gr II and III, as shown in Table 3 . In contrast, cases with positive IRF-1 expression were compared among the different groups. Significant difference was found between hemoglobin percentage, platelet count, prothrombin concentration, ALT, albumin, and AFP.
IRF-3 expression in relation to clinical and laboratory data
There was no significant difference between patients with positive and negative IRF-3 among the studied groups, as shown in Table 4 . In contrast, cases with positive IRF-3 expression were compared among the different groups. Significant difference was found regarding hemoglobin percentage, platelet count, prothrombin concentration, ALT, albumin, and AFP. Levels among patients with chronic HCV were significant compared with either levels of liver cirrhosis and HCC patients.
IRF-7 expression in relation to clinical and laboratory data
A statistically significant difference was found between patients with positive and negative IRF-7 regarding platelets and ALT of Gr I, and AFP of Gr III, as shown in Table 5 . In contrast, patients with positive IRF-7 expression were compared among the different groups. Significant difference was found regarding hemoglobin percentage, total leukocytic count, prothrombin concentration, albumin, and AFP among different groups.
Discussion
Infection with HCV frequently results in a persistent infection, suggesting that it has evolved efficient mechanism(s) for blocking the host cell's innate antiviral response. One of the most effective innate antiviral responses is the production of a/b IFN with subsequent induction of ISGs, whose products collectively limit virus replication and spread [6, 21] . Polymorphisms in these IFN-induced genes seem to be associated with HCV outcome [22] .
IFN-a is an important mediator for the host's innate antiviral defense system and an approved treatment for persistent viral infections. Functional polymorphisms in genes involved in IFN-a signaling and effector functions such as IRF-1 genotype are associated with the natural outcome of HCV infection and the responsiveness of chronic hepatitis C patients to IFN-a therapy [23] . After viral infection, IFN is produced in a biphasic fashion that involves a number of transcription factors, including the IRFs 1, 3, 7, and 9 [24, 25] . IRF-1, IRF-3, and IRF-7 have been identified as direct transducers of virus-mediated signaling and were shown to play a critical role in the induction of IFN genes. IRF-1 cooperates with IRF-3 and IRF-7 in the regulation of a range of antiviral genes, including the IFN-a and IFN-b genes [26, 27] . HCV regulation of IRF-1 may therefore impact other IRF pathways to influence host gene expression on a more global scale. Such regulation may create a more hospitable cellular environment for persistent HCV replication. To learn more about the possible underlying mechanisms of HCV infection persistence with subsequent progression of liver disease, we investigated the expression of IRF-1, IRF-3, and IRF-7 among patients with different stages of CLD.
In this study, the studied expression of IRF-1, IRF-3, and IRF-7 revealed differences in their expression among the enrolled patients. The prevalence of IRF-1 was most frequently towards patients with chronic HCV infection (86.6%), IRF-3 prevalence was most frequently towards patients with liver cirrhosis (73.3%), whereas there was Table 5 Comparison between cases with + ve and -ve IRF-7 of the different studied groups regarding lab results no statistically significant difference among the studied groups regarding the prevalence of IRF-7. The reported difference between the individual IRF could be because of the interaction between innate immune response and HCV with subsequent viral inhibition of host defenses and persistence of infection. In chronic HCV infection, there is an imbalance between an upregulated IFN-g system and a downregulated IFN-a and IFN-b system, probably because of a mixed effect exerted by HCVspecific and inflammatory nonspecific factors [28] . This is further supported by the ability of HCV to inhibit the activation of the endogenous IFN system that underlies its success in establishing a chronic infection [8] .
Expression of IRF-1 was more significantly detected in PBMC of patients with chronic HCV patients in contrast to that in the rest of the patients. The difference in the level of IRF-1 expression seems to be one of the factors that dictate how it functions. Expression of the IRF-1 gene is rapidly induced after virus infection and IFNs, proinflammatory cytokines, and high IRF-1 expression levels are required for the induction of a set of ISGs necessary for an efficient antiviral response [29, 30] . HCV-RNA replication affects IRF-1 expression, by downmodulating both mRNA and protein expression at levels no more sufficient to induce the expression of ISGs, the direct targets of IRF-1. Active IRF-1 binds within the ISRE and participates in the induction of cellular genes that impact virus replication either directly or through stimulation of the adaptive immune response [31] . Moreover, one of the nonstructural HCV proteins, NS5A, may influence HCV persistence by blocking IRF-1 activation and disrupting a host antiviral pathway that plays a role in suppressing virus replication [32] .
In contrast, IRF-1 expression was suppressed among HCV patients as found by previous studies that reported suppression of IRF-1 by HCV core protein which can be considered a unifying mechanism that recapitulates most of the data reported on the dysregulation of cellular processes induced by this protein and may at least partially account for its role in evading the host response at several levels: antiviral, inflammatory, and immune response. Thus restoration of the correct expression of IRF-1 in HCV-infected cells could, therefore, represent a new avenue for therapeutic interventions [14] .
Data reported in this study suggested low IRF-1 expression among HCC patients in contrast to the rest of the patients. Similarly, the expression of IRF-1 mRNA was lower in human HCC than in noncancerous liver tissue as reported by Tada et al. [33] . It is unclear how IRF-1 is inactivated in HCC. IRF-1 is considered to be an important tumor-suppressor gene in human malignancies, including HCC. IRF-1 was not decreased in welldifferentiated HCC and was less expressed in poorly differentiated HCC suggesting that IRF-1 is inactivated at a late stage of human hepatocarcinogenesis [34] .
In this study, IRF-3 was highly expressed in patients with liver cirrhosis in comparison with that in chronic HCV and HCC patients. Similarly, a recent study reported that HCV can transiently trigger IRF-3 activation during virus spread while in chronic HCV; IRF-3 activation within infected hepatocytes is limited. Furthermore, HCV NS3/4A serine protease can block the phosphorylation and effector action of IRF-3, a key cellular antiviral signaling molecule with subsequent suppression of HCV-RNA replication. Thus, the inhibition of NS3/4A protease may both block viral replication and restore IRF-3 control of HCV infection [35] . Persistent HCV infection is likely to depend on viral inhibition of host defenses, which could be evident by the low expression of IRF-3 in chronic HCV detected in our patients.
In contrary to our results which revealed high prevalence of IRF-3 in patients with liver cirrhosis, IRF-3 activation was found to induce a/b IFN production and ISG expression, which can limit viral infection through an innate immune response [36] and thus may account for an improved HCV outcome with stimulation of the host antiviral and antiproliferative gene products [6] .
Human IRF-7 is expressed effectively only in lymphoid tissues, PBMC, and some cell lines of lymphoid origin and its transcription can be further stimulated by treatment with IFN-a. However, none or very little expression of IRF-7 could be detected in established cell lines of fibroblast or epithelial origin [37] . IRF-7 has been shown to play an essential role in the transcriptional activation of virus-inducible cellular genes, especially IFN genes [38] . This study revealed that IRF-7 was detected with comparable rates among all of the studied groups without any significant difference denoting that IRF-7 expression could not be used as a marker in the progression of CLD. On the contrary, a recent study reported that polymorphisms of the IRF-7 gene, which can affect both the quality and the quantity of IRF-7, might be used as markers of host factors associated with a higher risk of cirrhosis in chronic HCV infection [38] . This inconsistency with our results regarding IRF-7 expression could be explained as the frequency of gene expression of IRF-7 was conducted on PBMC and not on hepatocytes in addition to the large samples used.
In addition to its role in innate immunity, IRF-7 modulated the expression of a large number of cellular genes, especially those categories of signal transduction, transcription factors, and apoptosis [39] . IRF-7 displayed an increment of the expression of genes encoding tumor necrosis factor-related apoptosis inducing ligand, IL-12, and IL-15 as well [40] . The nonsignificant expression of IRF-7 detected in this study among all stages of CLD could be because of the effect of IRF-7 on apoptosis which is a characteristic feature of HCV infection.
However, some limitations of this study deserve mentioning. The frequency of gene expression of IRF-1, IRF-3, and IRF-7 was conducted on PBMC and not on hepatocytes that harbor replicating HCV. Analysis of hepatocytes requires liver biopsy, an invasive procedure which cannot be carried out repeatedly. Responses in PBMC are more likely to reflect a global response and not be under the local control of replicating virus or disease activity, which may modulate IFN responses.
In conclusion, expression of IRF-1 was more significantly detected in PBMC of patients with chronic HCV patients in contrast to that in the rest of the patients. IRF-1 might be used as one of the host factors associated with a higher risk of disease progression with development of cirrhosis in patients with chronic HCV infection and subsequent HCC.
